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Background: Cell-based regeneration therapies have great potential for application in new areas in clinical medicine,
although some obstacles still remain to be overcome for a wide range of clinical applications. One major impediment
is the difficulty in large-scale production of cells of interest with reproducibility. Current protocols of cell therapy require
a time-consuming and laborious manual process. To solve this problem, we focused on the robotics of an automated
and high-throughput cell culture system. Automated robotic cultivation of stem or progenitor cells in clinical trials has
not been reported till date. The system AutoCulture® used in this study can automatically replace the culture medium,
centrifuge cells, split cells, and take photographs for morphological assessment. We examined the feasibility of this
system in a clinical setting.
Results: We observed similar characteristics by both the culture methods in terms of the growth rate, gene expression
profile, cell surface profile by fluorescence-activated cell sorting, surface glycan profile, and genomic DNA stability. These
results indicate that AutoCulture® is a feasible method for the cultivation of human cells for regenerative medicine.
Conclusions: An automated cell-processing machine will play important roles in cell therapy and have widespread use
from application in multicenter trials to provision of off-the-shelf cell products.
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Degenerative diseases affect increasing numbers of people,
particularly in developed countries with aging populations.
Despite advancements in medicine, modalities to cure ad-
vanced diseases are often not available. Therefore, regen-
erative therapy may become the standard treatment
option in cardiovascular medicine. Recent developments
in stem cell biology, including those related to induced
pluripotent stem cells (iPSCs) and tissue-derived stem/
progenitor cells, are a giant leap toward the goal. Recently,
myocardium-derived stem/progenitor cells were isolated
by several institutes [1-3]. These cell populations have the
potential to repair the diseased heart, and clinical trials are
currently ongoing.* Correspondence: gojos@koto.kpu-m.ac.jp
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reproduction in any medium, provided the orIn tandem with these developments in stem cell biology
and the large number of completed and ongoing clinical
trials, attempts have been made to commercialize these
therapies [4]. The most prominent therapeutic strategy is
cell transplantation. However, harvested cells or tissues
are usually limited in quantity and stem cells properties
may vary from batch to batch, hindering the reliability for
clinical applications. Moreover, current cell therapy proto-
cols are laboratory centered and labor intensive, requiring
highly skilled personnel and weeks to months to harvest
sufficient quantities of stem/progenitor cells from the iso-
lated tissues. These manual procedures are expensive and
can result in high phenotypic and yield variability between
different trials and institutions [5].
Strategies to validate advanced medicinal products have
been established; however, these “best practices” still de-
pend on the ability of personnel to perform them, such as
the cultivation of stem/progenitor cells under strictlyd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be achieved by automation, and several effective automatic
cell culture systems have been reported [7-12]. These au-
tomated platforms have the potential to provide cost-
effective, large-scale expansion of stem/progenitor cells
with consistent phenotype for clinical use and improved
operational safety [13]. Progress in robot platforms for cell
culture has resulted in several prototypes to implement
large-scale expansion and harvesting of stem/progenitor
cells with yield and phenotypic reproducibility. An auto-
mated culture system by “The Automation Partnership
Biosystems (TAP Biosystems)” has cultivated human em-
bryonic stem cells and bone marrow-derived cells [14,15].
Kawasaki Heavy Industries (Tokyo, Japan) has created
AutoCulture® (Additional file 1), which can automate
many manual steps in cell culture, including media ex-
change, centrifugation of cells, splitting and passaging, and
recording of cell morphology (Figure 1A). To the best of
our knowledge, no cell products obtained from an auto-
mated culture apparatus have actually been transplanted
into humans for regenerative therapy.Figure 1 Process maps showing the key steps in human cardiac stem
(A) The automated culture system AutoCulture® by Kawasaki Heavy Industr
good manufacturing practice (cGMP) grade. (B) Schematic representation o
split into 2 dishes for either manual culture or automated culture using AuOur institute recently completed a phase I clinical trial
using autologous cardiac stem cells (CSCs) isolated by
manual cell culture techniques to treat ischemic cardiomy-
opathy [16]. The trial is registered in the Japanese govern-
ment database for clinical trials using human stem cells and
ClinicalTrials.gov, which is a world-wide registry and results
database for clinical trials involving humans, as AutoLo-
gous Human CArdiac-Derived Stem Cell to Treat Ischemic
cArdiomyopathy (ALCADIA; Identifier: NCT00981006).
CSCs are manually cultivated by a single experienced inves-
tigator for approximately 1 month to minimize variability
of the final cell products. To advance this trial from a
single-center to a multi-center randomized trial, we evalu-
ated AutoCulture® by comparing the growth rate, morph-
ology, and phenotype of cells cultivated using this method
with those of manually cultured CSCs.
Results
Cellular morphology and growth
Calculations based on the net cell number and doubling
time obtained in the ALCADIA trial (Additional file 2)cell culture using manual methods and the AutoCulture® system.
ies (left) can automate every step of manual cell culture under current
f the experiment. Human cardiac stem cells (CSCs) were thawed and
toCulture®.
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to obtain the appropriate cell number for clinical trial
when cells after the second passage (P2) were used as the
starting material. Identically seeded culture plates were
maintained manually or by automation using AutoCulture®
(Figure 1B). The morphology of CSCs cultured using the
automated system was similar to that of manually cultured
CSCs on day 7 and 14 after seeding (Figure 2A). Under
both the conditions, the cells were of similar size, exhibited
a low nucleus/cytoplasm ratio, and had a spindle-like
shape. In addition, the growth rate was not significantly
different, as indicated by cell counts at passage (Figure 2B).
Trypan blue staining revealed no significant difference in
cell viability between the culture methods. Moreover, both
the methods effectively washed out the cells, as indicated
by the paucity of adherent cells on discarded culture dishes
(data not shown). These results suggest that manual pas-
sage was effectively replicated using AutoCulture®.
Gene expression
To investigate the gene expression profiles, RT-PCR ana-
lysis was performed according to the shipping criteria for
cultivated cells in the current clinical trial (ALCADIA). We
examined expression levels of the pluripotency related
genes NANOG, OCT4, SOX2, and REX1 and 2 transcrip-
tion factor genes involved in cardiomyocyte development,
NKX2.5 and GATA4 (Figure 2C). The stem cell markers
OCT4, REX1, and GATA4 were expressed by both cell pop-
ulations; however, neither NANOG nor NKX2.5 expressionFigure 2 Phenotypic characterizations of CSCs during manual and au
cultivated either by manual handling (upper panels) or using AutoCulture®
culture. (C) RT-PCR analysis of genes related to pluripotency and cardiac-spwas detectable. Moreover, expression levels were not sig-
nificantly different between the 2 groups on either day 7
or day 14.
Cell surface marker expression profiles
Cell surface markers indicative of CSCs and other pheno-
types were detected by fluorescence-activated cell sorting
(FACS) (Figure 3A). Under both the culture conditions, the
cells were positive for the mesenchymal stem cell (MSC)
markers CD29 and CD90 and the vascular endothelial
marker CD105 and negative for the hematopoietic lineage
marker CD45 and MHC class II. In addition, fluorescent in-
tensities measured by FACS were similar for all positive
markers, indicating that equal proportions of cells in both
the populations expressed these proteins. Moreover, almost
all the cells were CD29 positive, whereas at least 2 popula-
tions were distinguished on the basis of CD90 expression.
Furthermore, STRO-1, which is expressed by mesenchymal
stem cells in the bone marrow, was negative in both the
populations. Although the surface expression profiles of
CSCs and bone marrow-derived stem cells overlap, STRO-
1 expression can discriminate cardiac MSCs from bone
marrow-derived MSCs.
Surface glycan expression profile by lectin
microarray analysis
Recently, glycan expression profiling has been reported to
be an effective cell validation tool to complement pheno-
type analysis by epigenetic and gene expression analysestomated culture. (A) Phase contrast microphotographs of CSCs
(lower panels). (B) Growth rates of CSCs under manual or automated
ecific transcription factors.
Figure 3 Analysis of cell surface protein and glycan expression in CSCs expanded by manual culture or AutoCulture®. (A) Cells were
stained with fluorescence-conjugated primary antibodies and analyzed for surface expression by fluorescence-activated cell sorting. (B) Lectin
microarray analysis of manual cultures and cells maintained using AutoCulture® on day 7 and day 13/14. The glycan profiles showed little differ-
ence between the two culture groups at any time.
Kami et al. BMC Biotechnology 2013, 13:102 Page 4 of 9
http://www.biomedcentral.com/1472-6750/13/102[17]. These lectin profiles showed similar patterns, and no
significant differences in expression intensities were ob-
served between the 2 culture groups on either day 7 or
day 13/14 after seeding (Figure 3B). The washing process
used to harvest adherent cells may have profound effects
on the cell surface structure and expression. CSCs har-
vested from the AutoCulture® system exhibited similar
surface expression profiles and overall viability to those
cultured manually.
Analysis of array comparative genomic hybridization
(aCGH) and microarray
To detect genomic DNA mutations on AutoCulture®, we
performed aCGH analysis (Agilent technologies) on day 7
and day 14 and compared them with the tissue derived
from human right atrial appendage (RAA) (Figure 4A).
There were no differences in genomic DNA mutation be-
tween CSCs in AutoCulture® and RAA. To investigate the
global gene expression profile changes between CSCs in
manual culture and CSCs in AutoCulture®, we performed
a pairwise comparison of gene expression microarray datausing NIA array analysis [18]. The results revealed a similar
gene pattern between them (Figure 4B, Additional file 3).
The “Symbol” of 162 gene probes was left blank in 258
overexpressed gene probes.
Discussion
Cell-based regenerative medicine is still in the early stages
of development [19,20]. The quality of cells for transplant
depends on the ability of skilled personnel to isolate, ex-
pand, and harvest cultured cells. For consistency of cell
yield and phenotype, it is imperative that methodological
consistency is strictly maintained. Automation greatly en-
hances the consistency of culture conditions and may thus
reduce the variability in cell quality that is one of the great
impediments to the widespread application of cell-based
therapy till date. In this study, we used the automated cell
culture system AutoCulture® to expand human CSCs iso-
lated from the RAA for use in the ALCADIA clinical trial
designed to assess the safety of cell-based therapy for pa-
tients with ischemic cardiomyopathy. RAA-derived cells
containing CSCs exhibited similar growth rates and gene
Figure 4 Global analysis of gene expression and genomic DNA mutations. (A) Comparison of array comparative genomic hybridization
analysis. Human gDNA (from RAA) was compared to gDNA extracted from CSCs cultivated using AutoCulture® after 1 and 2 weeks using CGH
arrays (arrays G4413A). (B) Microarray analysis of gene expression profiles. The pairwise scatter plot presents differences in gene expression on day
7 after seeding between manually cultured CSCs and those cultured using AutoCulture®. Grey dots represent transcripts with a subthreshold
difference in expression. Red or green dots indicate those with at least a 3-fold difference in expression levels between the two groups. Gene
expression levels are depicted on a log2 scale. The number of differentially expressed genes is indicated above.
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tures. Thus, the AutoCulture® system effectively replicated
manual culture and demonstrated scalability and stability
in addition to safety and cost-effectiveness. Indeed, we
found no significant differences in phenotype between the
two culture methods. Cells in both the populations had
similar morphologies, mean growth rates, and expression
levels of genes associated with pluripotency and the mes-
enchymal lineage. In addition, the surface glycan profile
was virtually identical, while aCGH analysis revealed no
difference in genomic DNA mutation frequency. Finally,
the approximately 41,000-probe Agilent Whole Human
Genome Microarray chip G4112F showed that only ap-
proximately 1% of transcripts measured were significantly
under- or overexpressed. The successful transfer of man-
ual to automated cell culture may be attributable to the
high flexibility of the machine, which can faithfully copy
every step and condition, including media changes, split-
ting, and passaging in a controlled environment.
AutoCulture® is an all-in-one automated cell culture sys-
tem consisting of robot arms, tube and flask decappers,
flask holders, flask tappers, media pumps, a pipette head,a centrifugal separator, a rotating plate, and a CO2 incuba-
tor. In addition to media change and passage, it permits
routine observation. To automate these culture steps, it is
necessary to program the humidity, temperature, volume
and flow of liquid, and robot arm motion that transfers
flasks from or into the CO2 incubator or flask holder. An-
other automated cell culture platform, TAP CompacT, was
also shown to be an effective system for culture of adher-
ent cells by the Healthcare Engineering group [14]. How-
ever, the lack of a centrifugal separator in that system may
result in differences between the manual and automated
processes, possibly explaining why automation resulted in
a smaller population of STRO-1+ cells and overall lower
cell yield after the first passage [21]. STRO-1 expression is
not a necessary or specific marker for stem or progenitor
cells, and somatic stem cells may be more resistant to nu-
tritional and chemical stress [22]. Residual trypsin in the
culture media may have adversely affected the survival of
differentiated cells, but it is not clear whether stem or pro-
genitor cells can survive or not. On the other hand, the
AutoCulture® system efficiently removes trypsin/EDTA by
washing and centrifugation. There were no significant
Kami et al. BMC Biotechnology 2013, 13:102 Page 6 of 9
http://www.biomedcentral.com/1472-6750/13/102differences in the surface marker expression profile or the
mean rate of proliferation between these cells and those
maintained manually, strongly suggesting that both popu-
lations of RAA-derived CSCs contain equal properties.
The AutoCulture® system can save labor and costs by
expanding the scale of production and maintaining uni-
formity of results. In addition, this system can simultan-
eously cultivate different cells without cross-contamination
because it can be equipped with a connecting hatch to mul-
tiple CO2 incubators. Large-scale production and multi-
sample cell culture capacity for cell transplantation may be
a prerequisite for commercialization of cell products under
current good manufacturing practice (cGMP) grade. Pro-
duction methods for cell therapy should be designed to en-
sure that the end product is standardized and safe. cGMP
is a quality assurance system that ensures that the cell
product meets preset specifications with minimal lot-to-lot
variability [23]. It requires traceability of raw materials used
in cell culture and validated standard operating procedures
(SOPs) throughout the process [24,25]. Current good tissue
practice (cGTP) is intended to prevent human cells, tissues,
and cellular and tissue-based products from contamination
by infectious disease agents and to ensure that these cells
and tissues maintain their integrity and function. The con-
trolled environment of a carefully designed, constructed,
validated, and maintained clean room will minimize the
risks of environmental contamination and decrease the
possibility of cross-contamination [26]. Based on cGMP,
aseptic handling and filling of raw materials should be per-
formed in a grade A environment (class 100) with a grade
B background (class 1,000). Clean room disciplines, gown-
ing procedures, cleaning programs, and maintenance of air
handling units are included in SOPs. Environmental moni-
toring is essential in clean room quality control. Proper
cleaning, maintenance, repair, and attire are major issues
for cGMP [27].
Construction and maintenance of a cGMP facility is so
expensive that it may be difficult to conform to these stan-
dards on a large scale without automation. Unlike manual
culture, the robots enabled the environment in the cell
culture cabinet to be completely separated from the exter-
nal environment. Moreover, automated cell culture ma-
chines can be equipped with cleaning and monitoring
systems to prevent contamination by microorganisms and
cross-contamination by other cell types cultured in tan-
dem. These properties may meet the stringent conditions
for a human cell processing facility while reducing both
construction and maintenance costs.
In Japan, the regulatory path of a regenerative cell ther-
apy using this automated machine will be to obtain an ap-
proval for the end products, such as cells or tissues, based
on the new guidelines and philosophy at an initial phase.
An important requirement for obtaining approval is publi-
cation of the safety and reliability of the machine toproduce the final biological products in a peer-reviewed
journal. The similar properties of cell products between
those obtained by machine and those obtained by manual
culture, as demonstrated in this study, could support ap-
proval of a clinical trial using this machine, which is cur-
rently being planned.
Conclusion
AutoCulture® is one of the best candidates to solve the
problems inherent in large-scale production and harvest-
ing of human cells for clinical applications. The automated
cell processing system can reproduce many complex oper-
ations performed by professional staff and can maintain
multiple cell lines automatically. Thus, this automation
system will be a powerful tool for both clinical trials ex-
ploring the potential of autologous or allogeneic cell-based
regeneration therapies and for the commercialization.
Methods
Isolation of human CSCs containing atrial appendage
After this study was approved by the ethics committees of
Tokyo Metropolitan Geriatric Hospital (ID: #220106), hu-
man cardiac tissue samples from RAA were surgically ex-
cised from 7 patients (60–75 years old) during cardiac
surgery. All patients provided written informed consent. A
cell population containing CSCs was acquired according
to the current protocol for ALCADIA [28]. In brief, the
tissue fragments were cut into 5 × 5-mm pieces and incu-
bated with 0.2% collagenase type II and 0.1% DNase I
(Worthington Biochemicals) at 37°C for 30 min. The cells
were cultivated in a basic culture medium of Dulbecco’s
modified Eagle medium (DMEM)/F12 supplemented with
10% fetal bovine serum (FBS) and 40 ng/ml basic fibro-
blast growth factor (bFGF). The cells were seeded in 60-
mm dishes coated with collagen type I. The cultured cells
were passaged twice, harvested, and frozen until used in
this experiment. P2 cell population was utilized as the
starting material for this comparison experiment.
Cell expansion and harvesting
After thawing, the cells derived from the human atrium
were seeded at 1 × 105 cells per 100-mm culture dish
and cultivated for 5–7 days. The cells were split at 1:10
at 80%–90% confluence. The basic culture medium was
replaced every 3 or 4 days. For automated culture, we
used the same lot of CSCs. After seeding, the culture
dishes were placed in the AutoCulture® chamber and
transferred into the internal CO2 incubator by the robot
arm (Figure 1A, Additional file 4). For media replace-
ment, the robot arm retrieved the culture dishes from
the incubator and set them on a rotating table. The dish
covers were removed by the robot arm, a specified
amount of medium was discarded, fresh medium was
supplied by a new pipette, the covers were returned,
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incubator. For passage, the old medium was removed
and DPBS was pipetted onto the dishes under gentle
shaking. After washing in DPBS, AutoCulture® supplied
trypsin, oscillated the culture dishes, and returned them
to the CO2 incubator for a 5-min incubation. Following
this, the robot arm moved the culture dishes onto the
rotation table, added a prespecified volume of the basic
culture media, and transferred the cell suspension from
each dish to a separate 50-ml centrifuge tube. The cell
suspension was centrifuged at 200 × g for 5 min at room
temperature, and the supernatant was discarded. Fresh
basic culture medium was supplied to the cell pellet,
which was then resuspended. The washed cell suspen-
sion was subcultured at approximately 1:10 onto new
culture dishes and returned to the CO2 incubator.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cell populations contain-
ing CSCs, from human iPSCs, and raw human heart tis-
sue samples using the RNeasy Plus Mini Kit (QIAGEN)
as positive/negative control. Total RNA from human
iPSCs and the human heart (Clontech Laboratories)
was used as the positive control for each primer.
Total RNA (500 ng per reaction) was converted to
cDNA using the Transcriptor High Fidelity cDNA
Synthesis Kit (Roche Applied Science) according to
the manufacturer’s protocol. Primers for the cardiac-
specific transcription factors NKX2.5 and GATA4; the
stem cell markers NANOG, OCT3/4, SOX2, and
REX1; and the housekeeping gene GAPDH were ob-
tained from PrimerBank (Additional file 5).
Flow cytometric analysis
The cells (1 × 106 per reaction) were stained in autoMACS
Running Buffer (Miltenyi Biotec.) with fluorescence-
conjugated primary antibodies for 30 min at 4°C. The cells
were then analyzed on the Attune Acoustic Focusing Cyt-
ometer (Applied Biosystem), and the data were analyzed
using FlowJo 8.8.7 software (TOMY Digital Biology). Anti-
bodies used for phenotyping included anti-human CD29-
PE, CD90-PE, CD105-FITC, STRO-1-FITC, CD45-PE,
and MHC class II-PE. Isotype controls were FITC-
conjugated mouse IgG1, PE-conjugated mouse IgG1, and
FITC-conjugated mouse IgM.
Lectin microarray analysis
Proteins were extracted from each cell population in hydro-
phobic and hydrophilic fractions using the CelLytic MEM
Protein Extraction Kit (Sigma-Aldrich), as described previ-
ously [29]. Lectin microarray analysis was performed as de-
scribed previously, with only minor modifications [30].
The glycoprotein (200 ng) was labeled with Cy3 mono-
reactive dye (GE Healthcare) in DPBS containing 0.5%Triton X-100 (PBSTx) at room temperature for 1 h. The
Cy3-labeled glycoprotein solution (60 μl) was applied to the
LecChip (GP Bioscience), which has triplicate spots specific
for 45 lectins on each glass slide. An evanescent-field fluo-
rescence scanner (GlycoStationTM Reader) was used to
analyze the LecChip. All data were analyzed with GlycoSta-
tionTM Tools Signal Capture 1.0 and GlycoStationTM
Tools Pro 1.0 software (GP Bioscience). To expand the
dynamic range, the data were subjected to a gain-merging
procedure, and the merged data were then normalized
with max-normalization, as described previously [29].
aCGH analysis
Genomic DNA from the heart tissue and cultured cells was
isolated using the DNeasy Blood & Tissue Kit (QIAGEN).
Labeled test and reference DNAs were combined, dena-
tured, preannealed with Cot-1 DNA (Invitrogen) and block-
ing agent, and then hybridized to the arrays (SurePrint G3
Human CGH Microarray 2x400K, Agilent Technologies).
After hybridization and washing, the arrays were scanned
at 3-μm resolution using an Agilent G2505C scanner. Im-
ages were analyzed with Feature Extraction software
10.7.3.1 (Agilent Technologies) using the CGH 107 Sep09
protocol for background subtraction and normalization.
Gene expression analysis
Gene expression analysis was performed using the Agilent
Whole Human Genome Microarray chip G4112F (Agilent
Technologies), which contains >41,000 probes. Raw data
were normalized and analyzed by GeneSpring GX11 soft-
ware (Silicon Genetics). Pairwise scatter plot analysis of the
global gene expression profiles of both manually cultured
cells and autocultured cells was performed on day 7 after
thawing. The number of differentially expressed genes is in-
dicated over each scatter plot. The NIA Array [18] web tool
was used for pairwise scatter plot analysis. Gene expression
microarray data have been submitted under accession num-
ber GSE 44032. Analysis of microarray experiments was
conducted using the Aberration Detection Method-2 statis-
tical algorithm (Agilent Technologies) on the basis of the
combined log2 ratios at a threshold of 6.0. The data were
centralized, and calls with average log2 ratios <0.3219 were
filtered to exclude false positives.Additional files
Additional file 1: Document 1. Specialization of the automated cell
processing machine (Auto Culture®).
Additional file 2: Document 2. Quantitative cellular aspects for
ALCADIA clinical trial.
Additional file 3: Table S1. Results of microarray analysis of CSCs in
manual culture and AutoCulture®. To investigate the differences in global
gene expression profile between CSCs in manual culture and CSCs in
AutoCulture®, we performed a pairwise comparison of gene expression
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expression patterns between them.
Additional file 4: Movie 1. AutoCulture®.Movie of the culture robot in
AutoCulture®.
Additional file 5: Table S2. RT-PCR primer sequences. RT-PCR primer
sequences were obtained from PrimerBank (http://pga.mgh.harvard.edu/
primerbank/).
Abbreviation
CSC: Cardiac stem cells; FACS: Fluorescence-activated cell sorting;
MSCs: Mesenchymal stem cells; aCGH: Array comparative genomic
hybridization; RAA: Right atrial appendage; cGMP: Current good
manufacturing practice; SOPs: Standard operating procedures;
cGTP: Current good tissue practice; bFGF: Basic fibroblast growth factor.
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